格隆汇3月26日丨爱康医疗(01789.HK)公告，截至2024年12月31日止年度，集团实现收入约人民币13.46亿元，较2023年同期显著增长23.1%。集团截至2024年12月31日止年度实现净利润约人民币2.74亿元，较2023年同期显著增长50.4%。溢利增长主要归因于收入增长以及费用管控所致。董事议决，建议就截至2024年12月31日止年度派付末期股息每股股份7.2港仙。
2024年，在带量采购政策推动下，进一步加速进口替代，集团产品的手术量需求持续增长。手术量快速增长，进一步提升了集团产品在医院的覆盖率，也使得带量内产品销售获得进一步增长。同时，集团通过积极的市场开拓，以及在数字骨科全流程解决方案的带动下，海外手术量提升，海外收入获得显著的增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.